Coeptis Therapeutics Secures Exclusive Rights to Negotiate to Acquire Transformational Cell Therapy Platform to Enable Combinatorial IO Treatment Strategies April 6, 2023
Omega Enters Supply Agreement With Roche To Evaluate OTX-2002 – Atezolizumab combination in HCC April 6, 2023
Bicycle Therapeutics Announces a Strategic Collaboration with Novartis to Discover, Develop and Commercialize Bicycle® Radio-Conjugates April 6, 2023
First Patient dosed in the CaMMouflage Ph 1 Trial of CB-011 for the Treatment of R/R Multiple Myeloma April 6, 2023
First Patient Dosed in the Ph 2 Study, Harmonic™, for LP-300 in Never Smokers with Advanced NSCLC April 6, 2023
First Patient Dosed in ONSEMBLE Ph 2 Randomized Trial of Onvansertib in Patients with mCRC April 6, 2023
First Patient Dosed in Ph 1/1b Dose Escalation/Dose Expansion Study of PRGN-3007 in Advanced ROR1+ Hematological and Solid Tumors April 6, 2023
Interim results from Part 1 of Ph 3 RUBY trial of Jemperli + chemo in adult patients with primary advanced or recurrent endometrial cancer announced April 6, 2023
Ph 3 interim data analysis of RenovoGem therapy for pancreatic cancer patients to be announced April 6, 2023
Neoadjuvant Opdivo + chemo Demonstrate Long-Term, Durable Clinical Benefits in Resectable NSCLC at 3 Years in the CheckMate -816 Trial April 6, 2023
Positive Topline Data from BDC-1001 Ph 1 Dose-Escalation Trial in HER2-Expressing Tumors announced, Supporting Advancement to Ph 2 Clinical Studies April 6, 2023
New RYBREVANT (amivantamab-vmjw) Data Showed Long-Term Clinical Response and Safety in Patients with Advanced NSCLC with EGFR Exon 20 Insertion Mutations Who Have Failed Prior Platinum-Based Chemotherapy April 6, 2023
Updated Efficacy and Safety of Taletrectinib in Patients with ROS1-Positive NSCLC announced April 6, 2023
KEYTRUDA + Chemo Significantly Improved PFS vs chemo Alone as 1L Therapy for Advanced/Recurrent Endometrial Carcinoma, Regardless of Mismatch Repair Status April 6, 2023
Rolling Submission of NDA to U.S. FDA for Fruquintinib for the Treatment of Refractory mCRC completed April 6, 2023
Positive CHMP Opinion for Breyanzi for R/R Large B-cell Lymphoma After One Prior Therapy April 6, 2023
FDA Converts to Full Approval Indication for KEYTRUDA® for Certain Adult and Pediatric Patients With Advanced MSI-H or dMMR Solid Tumors April 6, 2023
